NCT04365647 is a clinical trial in Brain Tumor, Primary, sponsored by Sheri Kashmir Institute of Medical Sciences.

Who is sponsoring NCT04365647?

NCT04365647 is sponsored by Sheri Kashmir Institute of Medical Sciences.

What condition does NCT04365647 study?

NCT04365647 studies Brain Tumor, Primary.

Is NCT04365647 still recruiting?

NCT04365647 is currently completed. Last updated 28 April 2020.

Last reviewed 2020-04-28 · How we verify

NCT04365647

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intra-operative Variation in Size of Brain Tumors After Craniotomy

Completed Last updated 28 April 2020

What this trial tests

trial in Brain Tumor, Primary in 51 participants. Completed in 31 March 2020.

Timeline

1 March 2018

Primary endpoint
1 November 2019

31 March 2020

Quick facts

Lead sponsor	Sheri Kashmir Institute of Medical Sciences
Status	Completed
Study type	OBSERVATIONAL
Enrollment	51
Start date	1 March 2018
Primary completion	1 November 2019
Estimated completion	31 March 2020
Sites	1 location across India

Conditions studied

Brain Tumor, Primary — all drugs for Brain Tumor, Primary →

Sponsor

Sheri Kashmir Institute of Medical Sciences

Who can join

Adults 15 to 75, any sex, with Brain Tumor, Primary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We planned to evaluate the change in tumor dimensions of intraaxial parenchymal tumors after craniotomy by comparing the tumor size on intraoperative ultrasonography (IOUSG) with pre-operative CECT and CEMRI brain.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Brain Tumor, Primary

Currently open trials in the same condition.

NCT06185686 — Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients · recruiting
NCT06282562 — FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients · NA · recruiting
NCT05831631 — Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors · recruiting
NCT04427384 — Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) · recruiting
NCT05775458 — Glutamate Excitotoxicity and Its Role in Glioblastoma Biology · recruiting

Other Sheri Kashmir Institute of Medical Sciences trials

Trials by the same sponsor.

NCT04895540 — South Asian Arrhythmogenic Cardiomyopathy Registry · unknown
NCT04588909 — Outcomes of Elective Colorectal Cancer Surgery During COVID 19 Pandemic: Implications for Cancer Care Policy · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04365647 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sheri Kashmir Institute of Medical Sciences
Last refreshed: 28 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04365647.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing